Regulatory Update: Diphenidine Placement in Schedule I
The diphenidine regulatory scheduling update places this synthetic dissociative in Schedule I. This reflects concerns about its high abuse potential and no accepted medical use. Clinicians should monitor emerging patterns of diphenidine use amid evolving…
Schedules of Controlled Substances: DEA Synthetic Cannabinoids Schedule I Placement
The DEA synthetic cannabinoids schedule I placement 2026 update designates CUMYL-PEGACLONE as a Schedule I substance. This reflects the ongoing regulatory efforts to control potent synthetic cannabinoids. Clinicians should be aware of the unique clinical…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA scheduling updates include the temporary placement of 2-Fluorodeschloroketamine in Schedule I due to its abuse potential. This regulatory action highlights challenges in controlling novel synthetic substances. Clinicians should stay informed…
Schedules of Controlled Substances: Diphenidine Schedule I Placement
The DEA has placed diphenidine into Schedule I due to its abuse potential and lack of medical use. This diphenidine schedule I placement highlights challenges in regulating novel synthetic drugs. Clinicians should screen for diphenidine use alongside…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has designated synthetic cannabinoids schedule I designation for CUMYL-PEGACLONE due to its high abuse potential and no accepted medical use. This scheduling reflects ongoing regulatory efforts to control novel synthetic cannabinoids. Clinicians…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA has placed diphenidine in Schedule I, classifying it as a controlled substance with high abuse potential. Diphenidine is a synthetic dissociative drug posing public health risks. Awareness of diphenidine schedule I status aids clinicians in…